{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:25:06Z","timestamp":1792445106336,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03851-w","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T12:06:34Z","timestamp":1748693194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma"],"prefix":"10.1186","volume":"23","author":[{"given":"Fei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"3851_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma:2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"3851_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.V65.2.305.305","volume":"65","author":"PR Greipp","year":"1985","unstructured":"Greipp PR, Raymond NM, Kyle RA, O\u2019Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305\u201310.","journal-title":"Blood"},{"key":"3851_CR3","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","volume":"91","author":"PR Greipp","year":"1998","unstructured":"Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology\u2013an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501\u20137.","journal-title":"Blood"},{"issue":"4","key":"3851_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000206056","volume":"76","author":"M Di Stasi","year":"1986","unstructured":"Di Stasi M, Cavanna L, Paties C, Fornari F, Civardi G, Binelli F, Buscarini E, Buscarini L. Anaplastic myeloma as extramedullary relapse of multiple myeloma in remission. Case report and review of the literature. Acta Haematol. 1986;76(4):202\u20137.","journal-title":"Acta Haematol."},{"key":"3851_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36502\/2022\/ASJBCCR.6255","volume":"5","author":"J Wu","year":"2022","unstructured":"Wu J, Chu E, Chase CC, Choi T, Gasparetto C, Young K, Kang Y. Anaplastic Multiple Myeloma: Case Series and Literature Review. Asploro J Biomed Clin Case Rep. 2022;5:1\u201311.","journal-title":"Asploro J Biomed Clin Case Rep"},{"key":"3851_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PAP.0000000000000253","volume":"27","author":"BJ Chen","year":"2020","unstructured":"Chen BJ, Chuang SS. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. Adv Anat Pathol. 2020;27:61\u201374.","journal-title":"Adv Anat Pathol"},{"issue":"Suppl 1","key":"3851_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ijlh.13863","volume":"44 Suppl 1","author":"J Bailly","year":"2022","unstructured":"Bailly J, Jenkins N, Chetty D, Mohamed Z, Verburgh ER, Opie JJ. Plasmablastic lymphoma: An update. Int J Lab Hematol. 2022;44 Suppl 1(Suppl 1):54\u201363.","journal-title":"Int J Lab Hematol."},{"issue":"1","key":"3851_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12957-015-0649-8","volume":"13","author":"N An","year":"2015","unstructured":"An N, Li X, Shen M, Chen S, Huang Z. Analysis of clinical features, treatment response and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report. World J Surg Oncol. 2015;13(1):239\u201344.","journal-title":"World J Surg Oncol"},{"issue":"11","key":"3851_CR9","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","volume":"12","author":"J Blad\u00e9","year":"1994","unstructured":"Blad\u00e9 J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398\u2013404. https:\/\/doi.org\/10.1200\/JCO.1994.12.11.2398.","journal-title":"J Clin Oncol."},{"issue":"6","key":"3851_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-020-01060-w","volume":"35","author":"J Liu","year":"2021","unstructured":"Liu J, Hu X, Jia Y, Lu J, Lee JH, Kim K, Chen W, Liu A, Liu Y, Chen Q, Zhang C, Suh C, Kim MK, Zhou F, Chng WJ, Kumar SK, Durie B, Hou J, Fu W, Du J. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). Leukemia. 2021;35(6):1797\u2013802.","journal-title":"Leukemia"},{"key":"3851_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000447662","volume":"60","author":"R Beljan Perak","year":"2016","unstructured":"Beljan Perak R, Karaman I, Sundov D, Jakelic Pitesa J, Novak A, Pavlovic A. Anaplastic Variant of Plasma Cell Myeloma: A Pitfall of Morphlogical Identification. Acta Cytol. 2016;60:275\u20136.","journal-title":"Acta Cytol"},{"key":"3851_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosi\u00f1ol L, Usmani SZ, Zamagni ERichardson P. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"3851_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/ejh.14296","volume":"113","author":"Y Song","year":"2024","unstructured":"Song Y, Du J, Jin X, Li H, Jia C, Liu Y, Li K, Zhou D, Zhuang J. MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma. Eur J Haematol. 2024;113:824\u201332.","journal-title":"Eur J Haematol"},{"key":"3851_CR14","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.3390\/ijms241411259","volume":"24","author":"R McAvera","year":"2023","unstructured":"McAvera R, Quinn J, Murphy P, Glavey S. Genetic Abnormalities in Extramedullary Multiple Myeloma. Int J Mol Sci. 2023;24:11259.","journal-title":"Int J Mol Sci."},{"key":"3851_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.leukres.2013.09.025","volume":"37","author":"M Bahmanyar","year":"2013","unstructured":"Bahmanyar M, Qi X, Chang H. Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications. Leuk Res. 2013;37:1726\u20138.","journal-title":"Leuk Res"},{"issue":"7","key":"3851_CR16","first-page":"e63597","volume":"16","author":"MT Cunningham","year":"2024","unstructured":"Cunningham MT, Farrell D, Mostofizadeh S, Chopra S. Anaplastic Multiple Myeloma With a Novel Proliferation of Pleomorphic Binuclear Plasma Cells. Cureus. 2024;16(7):e63597.","journal-title":"Cureus"},{"issue":"1","key":"3851_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3960\/jslrt.19031","volume":"60","author":"M Saburi","year":"2020","unstructured":"Saburi M, Ogata M, Soga Y, Kondo Y, Kurimoto R, Itani K, Kohno K, Uchida H, Nakayama TJ. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma. Clin Exp Hematop. 2020;60(1):17\u201320.","journal-title":"Clin Exp Hematop"},{"key":"3851_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3960\/jslrt.17035","volume":"58","author":"S Ichikawa","year":"2018","unstructured":"Ichikawa S, Fukuhara N, Hatta S, Himuro M, Nasu K, Ono K, Okitsu Y, Kobayashi M, Onishi Y, Ri M, Ichinohasama RHarigae H,. Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission. J Clin Exp Hematop. 2018;58:39\u201342.","journal-title":"J Clin Exp Hematop"},{"key":"3851_CR19","doi-asserted-by":"publisher","first-page":"18792","DOI":"10.18632\/oncotarget.13320","volume":"8","author":"L Shi","year":"2017","unstructured":"Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X, Shang L, Tai YT, Feng X, Acharya P, Acharya C, Xu Y, Deng S, Hao M, Zou D, Zhao Y, Ru K. Qiu L An G, Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8:18792\u2013801.","journal-title":"Oncotarget"},{"issue":"1","key":"3851_CR20","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41598-020-58859-x","volume":"10","author":"A Romano","year":"2020","unstructured":"Romano A, Parrinello NL, Simeon V, Puglisi F, La Cava P, Bellofiore C, Giallongo C, Camiolo G, D\u2019Auria F, Grieco V, Larocca F, Barbato A, Cambria D, La Spina E, Tibullo D, Palumbo GA, Conticello C, Musto P, Di Raimondo F. High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling. Sci Rep. 2020;10(1):1983.","journal-title":"Sci Rep."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03851-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T12:06:35Z","timestamp":1748693195000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03851-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3851"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03851-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Beijing Chaoyang Hospital, Capital Medical University (Ethics Approval Number: 2021-ke-516\u20131) and has obtained informed written consent from all patients and healthy individuals. Also,this study complies with the Helsinki Declaration and adheres to the principles of honest and rigorous clinical practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}